Now that we've been looking back since May, RP sho

Now that we've been looking back since May, RP showed disagreement with the NP, it stopped coming up with it in the video at one point, obviously stopped mTNBC and so on. Now the most interesting is what are the reasons that have led the last 2 months to the distraction of RP and NP. I guess it was likely that the breakup was due to the money. In May, the NP said that CYDY finally had all the BPs wanted to demonstrate that Leronlimab could be a successful mono therapy for HIV-1. RP said that these channels of communication with BP had been interrupted and that they were working to restore that communication. Perhaps the RP has just been working on restoring communications. NP himself commented that BP returned to the table because of progress made with mono. Then they could get a low ball offer, perhaps $ 3-5 per share, which the NP refused, and RP could not refuse anything. In such a bid, he would receive at least $ 70 million for CYDY shares, a high position in BP and unlimited means to investigate Leronlimab for Cancers, which would enable him to obtain the Nobel Prize. Then the NP decided for TO and said it had opponents in CYDY and outside CYDY for such a move. If there were opponents around TO, it means that there was an alternative to financing that the NP refused, and there was obviously a distinction between RP and NP. An ex-wife of RP said in a comment that RP was only interested in money. RP is not long in CYDY and does not experience it as intimately as NP, so in a short time it would get very financially and in a career. How things are going to continue I do not know, maybe RP can sell their BP shares or support their possible offer to take over CYDY. Since everyone in CYDY has turned waarants into shares, and so many, they obviously know what the offer was and know that CYDY is worth much more than now, but given how many shares the RP has, it would in the shortest time profit most and the only one might get a very good position in BP with unlimited research resources. It would at least twice as fast as Leronlimab led to patients with metastases. This present situation is of course bad and opens up more questions than answers, but one is still certain that science is excellent.